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wild-type eNOS, and in increased release of 
heme-bound dioxygen as a superoxide anion 
(SS Gross, personal communication). 
 In conclusion, the study by Cherney  et al. , 3 
though not completely resolving the mystery 
of Glu298Asp substitution in eNOS, does pro-
mote the idea of the functional liability of this 
polymorphism. However, one should recog-
nize that a multitude of interpretations is bur-
ied within the super' cial simplicity of the 
 L -arginine challenge test. Future studies should 
address at least some of them by also using 
 D -arginine infusion (to rule out non-substrate 
actions) and performing western blotting of 
eNOS using N and C terminus-recognizing 
antibodies (to examine tissues for the presence 
of eNOS fragments). In the future, all these 
eM orts may become incorporated into indi-
vidualized preventive medicine. 
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of HIF signaling appears to be a two-
edged sword. Whereas proangiogenic and 
cytoprotective eM ects of HIF-dependent 
mediators under certain chronic renal 
disease conditions may have a protective 
function, 3 HIF eM ectors can be harmful; 
direct regulation of ' brinogenic factors, 
synergetic interaction with the pro' brotic 
transforming growth factor-  (TGF-  ), 
and the potential role of TGF-  in epithe-
lial-to-mesenchymal transition and in 
inflammation have the potential to 
perpetuate chronic kidney disease 
progression. 4 
 2 erefore, it is important to decode pre-
sumably cell type- and context-dependent 
HIF-related biological functions to 
develop therapeutic interventions that 
improve tissue oxygenation and halt the 
progression of ' brosis. Kojima  et al. 5 (this 
issue) demonstrate encouraging func-
tional interactions of the HIF pathway 
with other signaling pathways that are rel-
evant for basal cell functions such as pro-
tein-translation control or cell survival 
and apoptosis. 
 2 e approaches that the authors used to 
show the cross-links between HIF signal-
ing and other major intracellular signaling 
 Metallothionein: a new soldier 
in the fight against chronic renal 
hypoxia? 
 Reinhard  Bauer 1 
 Sustained hypoxia appears to be an early and pivotal condition in the 
pathogenesis of chronic kidney disease, and may induce a number of 
adaptive / protective or harmful cellular responses. Kojima and 
colleagues found an upregulation of metallothioneins (MTs) among 
dozens of altered expression patterns. They demonstrated the 
astonishing properties of MTs within major intracellular signaling 
pathways beyond their notorious functions in heavy metal metabolism, 
detoxification, and ROS scavenging — HRE stimulation during normoxia 
and hypoxia together with ERK phosphorylation and mTOR activation. 
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 A decline in renal oxygenation can pre-
cede matrix accumulation in chronic kid-
ney diseases, suggesting that sustained 
ischemic hypoxia above the necrotic 
threshold may initiate and promote tubu-
lointerstitial ' brosis. 2 is can cause pro-
gressive renal dysfunction and tissue 
destruction, the ' nal common pathway 
leading to end-stage renal failure. 1 Con-
sequently, hypoxia-inducible transcrip-
tion factors (HIFs), the master switches of 
oxygen-dependent gene regulation, 
appear to play a crucial role in the dynam-
ics and fate of poorly oxygenated renal 
tissue. In contrast to acute renal ischemia –
 reperfusion injuries, wherein HIF target 
genes are mainly involved in cellular 
mechanisms that improve outcome by 
increased hypoxia tolerance or enhanced 
oxygen availability, 2 long-term activation 
see original article on page 268
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pathways within the complex molecular 
pathogenesis of chronic kidney disease 
may be promising — for example, micro-
array analysis in well-designed animal 
models, which reflect the temporal 
sequence of an initial (mainly) pure 
hypoxic state of the injured kidney with 
subsequent evolving tissue destruction. 
Kojima  et al. 5 used the unilateral renal 
artery stenosis model in rats and obtained 
cortical tissue samples at time points of 
sustained tissue hypoxia. 2 is was veri' ed 
using rats harboring a transgene composed 
of hypoxia response element (HRE) and 
the FLAG-tagged luciferase reporter gene, 
which indicates hypoxic cells by showing 
an HIF-mediated cellular hypoxic 
response. 2 ey further identi' ed altered 
expression patterns of 96 genes following 
renal artery stenosis, including those genes 
coding for growth factors, kinases, and 
adhesion molecules, and validated them 
by quantitative reverse transcription 
polymerase chain reaction. Among these, 
an upregulation of metallothioneins (MTs) 
was encountered and further analyzed. 
 Indeed, these proteins, rich in cysteine 
( ~ 30 % of the amino acids) and of low 
molecular weight (6 – 7 kilodaltons), rep-
resent a group of non-enzymatic multi-
functional proteins with multifaceted 
protective capacities due to a variety of 
cell-stress situations. MT-I and MT-II are 
the most prevalent of the four known MT 
isoforms; MT-III is expressed mainly in 
the brain, and MT-IV is expressed in 
certain squamous epithelia. 2 is highly 
conserved family of closely related 
stress response proteins has the ability to 
bind and hence neutralize toxic (such as 
cadmium and mercury) and excess non-
toxic (such as zinc and copper) heavy 
metal ions and is centrally involved in the 
homeostatic regulation of zinc concentra-
tion. MTs also act as potent radical scav-
engers and protect against electrophilic 
antineoplastic agents, various mutagens, 
ionizing radiation, and nitric oxide. 
2 ey are also highly inducible and tran-
scriptionally activated by a variety of 
initiators, including divalent heavy 
metals, proinflammatory mediators, 
glucocorticoids, reactive oxygen and 
nitrogen species, and toxic organic 
compounds. 6 
 It is therefore not surprising that aber-
rant expression patterns of MT are cor-
related with a number of pathologic 
conditions, such as hypoxia. An intriguing 
feature of MT regulation is its involvement 
in the regulation of speci' c transcription 
factor activity, such as that of HIF, as 
shown by prevailing evidence from stud-
ies on the molecular pathogenesis of solid 
tumor carcinogenesis. 2 e fateful malig-
nant progression heavily depends on 
oxygen deprivation-related aberrant mod-
i' cations of signaling pathways and their 
downstream transcription factors, induced 
by microenvironmental hypoxia due to 
malfunction and malformation of blood 
vessels. In a variety of carcinoma cell lines, 
MT is transcriptionally activated by 
hypoxia through metal response elements, 
binding metal transcription factor-I 
(MTF-I) in their proximal promoter 
regions, which is essential for basal 
promoter activity and for induction by 
hypoxia, although other elements contrib-
ute to the full transcriptional response. 
Subsequently, sustained hypoxia results in 
an interplay between HIF-1  and MTF-I 
as a central regulator of metal-inducible 
expression of MT-I and MT-II. Indeed, 
MTF-I participates in the stabilization and 
nuclear accumulation of the HIF-1  pro-
tein. A recent study provides evidence for 
recruitment of MTF-I, HIF-1  , and p300 
to the MT-I promoter and indicates that 
MTF-I and HIF-1  are components of a 
transcriptional complex in response to 
hypoxia. 7 2 ereby, a marked accumula-
tion of MT appeared in the hypoxic cells. 
A similar crosstalk by transactivation 
between MTF-I and HIF-1 in the hypoxic 
kidney remains to be elucidated. 
 Nevertheless, in immortalized rat prox-
imal tubular cells, the authors observed 
a surprising eM ect of administration of 
MT-I into the medium. Upregulation of 
HRE activity occurred under normoxic as 
well as hypoxic conditions and in a dose-
dependent manner, followed by increased 
activity of representative HIF target genes, 
such as encoding for VEGF, Glut-1, and 
HO-1. 2 is raised the question of how the 
HIF complex can be stabilized by MT 
administration. HIF-1 (expressed in kid-
ney tubular epithelial cells) and HIF-2 
 Figure 1  |  Proposed diagram of the complex pathway stimulating HIF stabilization and 
translation during hypoxia in kidney tubular cells, influenced by MT-I. In contrast to a 
common inhibition of mTOR activity and reduction of protein translation by hypoxia (not shown), 
an activity of mTOR is maintained during hypoxia due to hypoxia-stimulated influx of calcium 
through protein kinase C-  (PKC-) activation 10 and of reactive oxygen species (ROS) through ERK 
activation. Hence, this may rescue part of mTOR activity by inhibiting the mTOR suppressor TSC1. 
Furthermore, oxygen deprivation resulting in ATP depletion induces an increase in the AMP:ATP 
ratio with related AMP protein kinase (AMPK) activation and tuberin (TSC2) phosphorylation and 
thereby causes TSC1 inhibition. TSC1 inhibition leads to a positive feedback of hypoxia-induced 
HIF upregulation via the stress response gene  REDD . Kojima  et al. 5 demonstrate MT-I upregulation 
during chronic renal hypoxia, presumably transcriptionally activated through metal response 
elements (MRE). MT-I administration evokes hypoxia response element (HRE) stimulation, possibly 
by ERK phosphorylation. Arrows indicate activation; bars indicate inhibition. 
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(expressed in glomerular cells, peritubular 
endothelial cells, and interstitial ' bro-
blasts) are members of the Per-ARNT-Sim 
family of basic helix-loop-helix transcrip-
tion factors and consist of an oxygen-sen-
sitive   -subunit and a constitutively 
expressed   -subunit, also known as the 
aryl hydrocarbon-receptor nuclear trans-
locator or simply HIF-  . HIF activation is 
dependent on stabilization of the oxygen-
sensitive   -subunit and its subsequent 
translocation to the nucleus, where it 
dimerizes with HIF-  and recruits tran-
scriptional cofactors such as CBP and 
p300. 8 Under conditions of adequate oxy-
gen supply, hydroxylated HIF-  binds to 
the von Hippel-Lindau tumor suppressor 
protein (pVHL), which is part of an 
E3 – ubiquitin ligase complex that targets 
HIF-  for proteasomal degradation. 2 e 
pVHL – HIF-   interaction is highly 
conserved between species and requires 
iron- and oxygen-dependent hydroxyla-
tion of two speci' c proline residues within 
the oxygen-dependent degradation 
domain of HIF-  . Prolyl-hydroxylation by 
prolyl hydroxylase domain (PHD) pro-
teins and binding to pVHL are absolutely 
required for the execution of HIF prote-
olysis under normoxia. 2 e second type 
of oxygen sensor controlling the hypoxic 
response is an asparaginyl hydroxylase, 
referred to as factor inhibiting HIF-1 
(FIH). 2 is enzyme hydroxylates an aspar-
agine residue in the most carboxy-termi-
nal transcriptional activation domain 
(C-TAD) of human HIF-1  . 2 is covalent 
modi' cation abrogates C-TAD interac-
tion with transcriptional coactivators, 
such as p300 and its paralogue CBP. 2 us, 
the two metabolic sensors, PHD and FIH, 
by controlling both the destruction and 
the inactivation of HIF-  subunits, ensure 
full repression of the HIF pathway in well-
oxygenated cells. 9 Because Kojima and 
co-workers 5 eliminated a possible iron-
chelating eM ect of MT by inducing HIF 
activation under normoxia, other essential 
components of HIF-  degradation must 
now be inhibited. Whether a direct pro-
tein – protein interaction between HIF-  
and MT (described for the intracellular 
domain of Notch, which underscores the 
importance of HIF-  as a regulator 
of important intracellular pathways, 
independent of its role in HRE-mediated 
transcription) or other factors (such as 
cellular ascorbate depletion resulting in 
oxidant stress and PHD inhibition) could 
be responsible remains to be clari' ed. 
 Kojima and co-workers 5 describe 
another intriguing observation ( Figure 1 ): 
an inhibitory in4 uence of rapamycin on 
HRE activity during MT-I stimulation 
under both normoxic and hypoxic condi-
tions, suggesting a speci' c MT-I-induced 
and mTOR-mediated transcriptional 
stimulation of HIF target genes. As a chief 
orchestrator of protein synthesis to regu-
late cell growth and metabolism in 
response to environmental cues, the 
mTOR pathway integrates a variety of sig-
nals downstream from growth factors as 
well as nutrient inputs in the form of 
amino acid, glucose, and oxygen availabil-
ity. Because rapamycin strongly inacti-
vates mTOR signaling via the mTORC1 
complex (raptor, which controls transla-
tion of critical growth genes including 
 HIF1A ), it appears reasonable that MT 
can displace an inhibitory eM ect of hypoxia 
on mTOR signaling. In contrast, oxygen 
deprivation resulting in ATP depletion 
increased the AMP:ATP ratio with related 
AMP protein kinase activation and 
tuberin (TSC2) phosphorylation and 
thereby caused mTORC1 inhibition. Fur-
thermore, hypoxia is transduced to 
mTORC1 via the two homologous pro-
teins REDD1 and REDD2. 2 e expression 
of REDD is upregulated upon hypoxia by 
the transcription factor HIF-1. REDD acts 
downstream of Akt and upstream of 
TSC1-TSC2 to inhibit mTORC1 signal-
ing. 11 2 e observation that MT-I stimula-
tion activated the ERK1 / 2 but not the 
PI3 / Akt pathway demonstrates the need 
for an in-depth analysis to clarify the pre-
sumptive target mechanism of the novel 
defense potential of MT in protecting 
against chronic hypoxia in the kidney. 
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